- Verastem (NASDAQ:VSTM) appoints of industry veteran Frank Neumann, M.D., Ph.D., as chief medical officer to oversee the company’s clinical and regulatory strategy and medical affairs team.
- Appointment reflects progress of the company's RAS targeted therapy development program.
- Company recently initiated registration-directed trials with VS-6766 and defactinib in recurrent low-grade serous ovarian cancer and KRAS mutant non-small cell lung cancer.
- “Frank brings deep expertise across the full spectrum of clinical and regulatory activities in all stages of Oncology drug development. His strong industry experience and commitment to urgently addressing the high unmet needs of patients will be critical to delivering novel treatments and establishing the backbone of RAS targeted therapy as we move forward with our registration-directed trials of VS-6766 and defactinib.” commented Brian Stuglik, CEO.
- Press Release